Suvoda has rebranded and added electronic consent and outcome assessment technologies to its offerings. The company announced the rebranding this week, explaining the fresh look will better position it to serve the evolving needs of sponsors and CROs.
The new consent technology was designed as clinical trials undergo a major shift in complexity and patient centricity, CEO Jagath Wanninayake told Fierce Biotech. This has forced CROs to adapt quickly.
The new eConsent technology now captures and manages patient consent electronically and adds the information into Suvoda’s interactive response technology system that manages patient and material logistics.
Suvoda’s electronic clinical outcome assessment (eCOA) system is also built around patient interaction, allowing pharma and biotech customers to report outcomes and gain access to related data.
“This powerful combination is unique in the market and offers significant flexibility and adaptability to keep trials on track,” Wanninayake said.
The increasing popularity of decentralized and hybrid trial models—in which patients take part in studies at home and site visits are minimized—is also changing what sponsors and CROs expect of technologies.
“When COVID began, decentralization went from being a nice-to-have to a must-have. Without it, trials could not progress,” Wanninayake said. “This was especially true for complex trials that deliver life-saving therapies. This rapidly increased their complexity, putting patients at the center of the operational logistics—more so than ever before.”
Demand for hybrid trials is here to stay, according to Wanninayake.
“Just as we will never again return to a pre-pandemic office environment, where remote working isn’t part of the mix, the clinical trial landscape will, for the foreseeable future, include aspects of decentralization,” he said.